語系:
繁體中文
English
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Lung Inflammation in Health and Dise...
~
SpringerLink (Online service)
Lung Inflammation in Health and Disease, Volume II
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Lung Inflammation in Health and Disease, Volume II/ edited by Yong-Xiao Wang.
其他作者:
Wang, Yong-Xiao.
面頁冊數:
XVI, 384 p. 42 illus., 29 illus. in color.online resource. :
Contained By:
Springer Nature eBook
標題:
Pneumology/Respiratory System. -
電子資源:
https://doi.org/10.1007/978-3-030-68748-9
ISBN:
9783030687489
Lung Inflammation in Health and Disease, Volume II
Lung Inflammation in Health and Disease, Volume II
[electronic resource] /edited by Yong-Xiao Wang. - 1st ed. 2021. - XVI, 384 p. 42 illus., 29 illus. in color.online resource. - Advances in Experimental Medicine and Biology,13042214-8019 ;. - Advances in Experimental Medicine and Biology,889.
1. Can GPCRs be targeted to control inflammation in asthma? -- 2. Cellular and molecular processes in pulmonary hypertension -- 3. INFLAMMATORY PATHWAYS IN SARCOIDOSIS -- 4. Innate Immune Responses and Pulmonary Diseases -- 5. Interstitial Lung Disease associated with Connective Tissue Diseases -- 6. Molecular mechanisms of vascular damage during lung injury -- 7. Neurotrophin Regulation and Signaling in Airway Smooth Muscle -- 8. Novel Thoracic MRI approaches for the assessment of pulmonary physiology and inflammation -- 9. Overview on Interactive Role of Inflammation, Reactive Oxygen Species and Calcium signaling in Asthma, COPD and Pulmonary Hypertension -- 10. Protein S-palmitoylation and lung diseases -- 11. Redox role of ROS and inflammation in pulmonary diseases -- 12. Semaphorin3E/PlexinD1 axis in asthma: what we know so far -- 13. Serine protease inhibitors to treat lung inflammatory diseases -- 14. Sex and Gender Differences in Lung Disease -- 15. Sex hormones and lung inflammation -- 16. Synopsis of Clinical Acute Respiratory Distress Syndrome (ARDS).
Lung diseases are leading causes of death and disability globally, with about 65 million people suffering from COPD, and 334 million from asthma. Each year, tens of millions of people develop and can die from lung infections such as pneumonia and TB. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and local inflammation can in turn cause systemic inflammation. There is increasing evidence of the coexistence of systemic and local inflammation in patients suffering from asthma, COPD, and other lung diseases, and the co-morbidity of two or more local inflammatory diseases often occurs. For example, rheumatoid arthritis frequently occurs together with, and promotes the development of, pulmonary hypertension. This co-morbidity significantly impacts quality of life, and can result in death for some patients. Current treatment options for lung disease are neither always effective, nor condition-specific; there is a desperate need for novel therapeutics in the field. Additionally, the molecular and physiological significance of most major lung diseases is not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signalling pathways, and cellular processes within lung disease, as well as basic and clinical technology, drug discovery, diagnoses, treatment options, and predictive prognoses. This is the first text to aggregate these developments. In two comprehensive volumes, experts from all over the world present state-of-the-art advances in the study of lung inflammation in health and disease. Contributing authors cover well-known as well as emerging topics in basic, translational, and clinical research, with the aim of providing researchers, clinicians, professionals, and students with new perspectives and concepts. The editors hope these books will also help to direct future research in lung disease and other inflammatory diseases, and result in the development of novel therapeutics.
ISBN: 9783030687489
Standard No.: 10.1007/978-3-030-68748-9doiSubjects--Topical Terms:
668561
Pneumology/Respiratory System.
LC Class. No.: QR180-189.5
Dewey Class. No.: 616.079
Lung Inflammation in Health and Disease, Volume II
LDR
:04735nam a22004095i 4500
001
1054590
003
DE-He213
005
20210815050558.0
007
cr nn 008mamaa
008
220103s2021 sz | s |||| 0|eng d
020
$a
9783030687489
$9
978-3-030-68748-9
024
7
$a
10.1007/978-3-030-68748-9
$2
doi
035
$a
978-3-030-68748-9
050
4
$a
QR180-189.5
072
7
$a
MJCM
$2
bicssc
072
7
$a
MED044000
$2
bisacsh
072
7
$a
MJCM
$2
thema
082
0 4
$a
616.079
$2
23
245
1 0
$a
Lung Inflammation in Health and Disease, Volume II
$h
[electronic resource] /
$c
edited by Yong-Xiao Wang.
250
$a
1st ed. 2021.
264
1
$a
Cham :
$b
Springer International Publishing :
$b
Imprint: Springer,
$c
2021.
300
$a
XVI, 384 p. 42 illus., 29 illus. in color.
$b
online resource.
336
$a
text
$b
txt
$2
rdacontent
337
$a
computer
$b
c
$2
rdamedia
338
$a
online resource
$b
cr
$2
rdacarrier
347
$a
text file
$b
PDF
$2
rda
490
1
$a
Advances in Experimental Medicine and Biology,
$x
2214-8019 ;
$v
1304
505
0
$a
1. Can GPCRs be targeted to control inflammation in asthma? -- 2. Cellular and molecular processes in pulmonary hypertension -- 3. INFLAMMATORY PATHWAYS IN SARCOIDOSIS -- 4. Innate Immune Responses and Pulmonary Diseases -- 5. Interstitial Lung Disease associated with Connective Tissue Diseases -- 6. Molecular mechanisms of vascular damage during lung injury -- 7. Neurotrophin Regulation and Signaling in Airway Smooth Muscle -- 8. Novel Thoracic MRI approaches for the assessment of pulmonary physiology and inflammation -- 9. Overview on Interactive Role of Inflammation, Reactive Oxygen Species and Calcium signaling in Asthma, COPD and Pulmonary Hypertension -- 10. Protein S-palmitoylation and lung diseases -- 11. Redox role of ROS and inflammation in pulmonary diseases -- 12. Semaphorin3E/PlexinD1 axis in asthma: what we know so far -- 13. Serine protease inhibitors to treat lung inflammatory diseases -- 14. Sex and Gender Differences in Lung Disease -- 15. Sex hormones and lung inflammation -- 16. Synopsis of Clinical Acute Respiratory Distress Syndrome (ARDS).
520
$a
Lung diseases are leading causes of death and disability globally, with about 65 million people suffering from COPD, and 334 million from asthma. Each year, tens of millions of people develop and can die from lung infections such as pneumonia and TB. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and local inflammation can in turn cause systemic inflammation. There is increasing evidence of the coexistence of systemic and local inflammation in patients suffering from asthma, COPD, and other lung diseases, and the co-morbidity of two or more local inflammatory diseases often occurs. For example, rheumatoid arthritis frequently occurs together with, and promotes the development of, pulmonary hypertension. This co-morbidity significantly impacts quality of life, and can result in death for some patients. Current treatment options for lung disease are neither always effective, nor condition-specific; there is a desperate need for novel therapeutics in the field. Additionally, the molecular and physiological significance of most major lung diseases is not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signalling pathways, and cellular processes within lung disease, as well as basic and clinical technology, drug discovery, diagnoses, treatment options, and predictive prognoses. This is the first text to aggregate these developments. In two comprehensive volumes, experts from all over the world present state-of-the-art advances in the study of lung inflammation in health and disease. Contributing authors cover well-known as well as emerging topics in basic, translational, and clinical research, with the aim of providing researchers, clinicians, professionals, and students with new perspectives and concepts. The editors hope these books will also help to direct future research in lung disease and other inflammatory diseases, and result in the development of novel therapeutics.
650
2 4
$a
Pneumology/Respiratory System.
$3
668561
650
2 4
$a
Molecular Medicine.
$3
668353
650
2 4
$a
Human Physiology.
$3
668349
650
0
$a
Respiratory organs—Diseases.
$3
1254083
650
0
$a
Molecular biology.
$3
583443
650
0
$a
Human physiology.
$3
636012
650
0
$a
Immunology.
$3
592892
700
1
$a
Wang, Yong-Xiao.
$4
edt
$4
http://id.loc.gov/vocabulary/relators/edt
$3
1020727
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer Nature eBook
776
0 8
$i
Printed edition:
$z
9783030687472
776
0 8
$i
Printed edition:
$z
9783030687496
776
0 8
$i
Printed edition:
$z
9783030687502
830
0
$a
Advances in Experimental Medicine and Biology,
$x
0065-2598 ;
$v
889
$3
1253792
856
4 0
$u
https://doi.org/10.1007/978-3-030-68748-9
912
$a
ZDB-2-SBL
912
$a
ZDB-2-SXB
950
$a
Biomedical and Life Sciences (SpringerNature-11642)
950
$a
Biomedical and Life Sciences (R0) (SpringerNature-43708)
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼[密碼必須為2種組合(英文和數字)及長度為10碼以上]
登入